N
Nathaniel D. Kirkpatrick
Researcher at Harvard University
Publications - 36
Citations - 3136
Nathaniel D. Kirkpatrick is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 21, co-authored 36 publications receiving 2727 citations. Previous affiliations of Nathaniel D. Kirkpatrick include University of Arizona.
Papers
More filters
Journal ArticleDOI
Bicarbonate increases tumor pH and inhibits spontaneous metastases
Ian Robey,Brenda Baggett,Nathaniel D. Kirkpatrick,Denise J. Roe,Julie Dosescu,Bonnie F. Sloane,Arig Ibrahim Hashim,David L. Morse,Natarajan Raghunand,Robert A. Gatenby,Robert J. Gillies +10 more
TL;DR: Oral NaHCO(3) selectively increased the pH of tumors and reduced the formation of spontaneous metastases in mouse models of metastatic breast cancer, suggesting that inhibition of this tumor acidity will reduce the incidence of in vivo metastases.
Journal ArticleDOI
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
TL;DR: Recent preclinical and clinical data that support the potential use of anti-CXCL12 agents (e.g., AMD3100, NOX-A12, or CCX2066) as sensitizers to currently available therapies by targeting the CXCL 12/CXCR4 and CXCR7 pathways are discussed.
Journal ArticleDOI
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper,Lars Riedemann,Zohreh Amoozgar,Giorgio Seano,Katharina Susek,Veronica Yu,Nisha Dalvie,Robin L. Amelung,Meenal Datta,Jonathan W. Song,Vasileios Askoxylakis,Jennie Taylor,Christine Lu-Emerson,Ana Batista,Nathaniel D. Kirkpatrick,Keehoon Jung,Matija Snuderl,Alona Muzikansky,Kay Stubenrauch,Oliver Krieter,Hiroaki Wakimoto,Lei Xu,Lance L. Munn,Dan G. Duda,Dai Fukumura,Tracy T. Batchelor,Rakesh K. Jain +26 more
TL;DR: It is shown that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels.
Journal ArticleDOI
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Teresa Peterson,Nathaniel D. Kirkpatrick,Yuhui Huang,Christian T. Farrar,Koen A. Marijt,Jonas Kloepper,Meenal Datta,Zohreh Amoozgar,Giorgio Seano,Keehoon Jung,Walid S. Kamoun,Trupti Vardam,Matija Snuderl,Jermaine Goveia,Sampurna Chatterjee,Ana Batista,Alona Muzikansky,Ching Ching Leow,Lei Xu,Tracy T. Batchelor,Dan G. Duda,Dai Fukumura,Rakesh K. Jain +22 more
TL;DR: Dual inhibition of VEGFR/Ang-2 prolongs survival in preclinical GBM models by reducing tumor burden, improving normalization, and altering TAMs, which may represent a potential therapeutic strategy to overcome the limitations of anti-VEGFR monotherapy in GBM patients.
Journal ArticleDOI
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
Matija Snuderl,Ana Batista,Nathaniel D. Kirkpatrick,Carmen Ruiz de Almodovar,Lars Riedemann,Elisa C Walsh,Rachel A. Anolik,Yuhui Huang,John D. Martin,Walid S. Kamoun,Ellen Knevels,Thomas Schmidt,Christian T. Farrar,Benjamin J. Vakoc,Benjamin J. Vakoc,Nishant Mohan,Nishant Mohan,Euiheon Chung,Sylvie Roberge,Teresa Peterson,Carlos Bais,Boryana H. Zhelyazkova,Stephen Yip,Martin Hasselblatt,Claudia Rossig,Elisabeth Niemeyer,Napoleone Ferrara,Michael Klagsbrun,Michael Klagsbrun,Dan G. Duda,Dai Fukumura,Lei Xu,Peter Carmeliet,Rakesh K. Jain +33 more
TL;DR: It is reported that placental growth factor (PlGF) is expressed in the majority of medulloblastomas, independent of their subtype, and shown that PlGF acts through Nrp1-and not vascular endothelial growth factor receptor 1-to promote tumor cell survival.